The end of the drugmaking supply chain was not quite as healthy last quarter for one of the world's largest drug distributors. AmerisourceBergen ($ABC) said its net income was up to $168.6 million, or 71 cents per share, from 62 cents per share a year earlier, but also said its operating income in its pharmaceutical distribution business was down, Reuters reports. The problem? Customers were selling less expensive drugs and business in Canada was not so good. The company said that was offset some by growth in its higher margin specialty distribution businesses. AmerisourceBergen was on a buying binge last year and last month picked up logistics and transport company World Courier for $520 million. Last year, AmerisourceBergen divided itself into three operations, AmerisourceBergen Drug Corp. (ABDC), focusing on high-volume pharmaceutical product distribution; AmerisourceBergen Specialty Group (ABSG) for specialty products like oncology drugs and plasma products; and AmerisourceBergen Consulting Services (ABCS), which does patient services and strategic consulting, as well as contract and clinical packaging. Story | More